 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second...

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously...

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 76,900 shares, a drop of 25.3% from the June 15th total of 103,000 shares. Approximately 0.5% of the shares of the ...

Rafael Holdings, Inc. (NYSE:RFL) Sees Large Decrease in Short Interest

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a binding...

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first...

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement...

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

Announces expanded search for strategic opportunities beyond biopharmaNEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. We remain ...

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Aptus Capital Advisors LLC bought a new stake in Rafael Holdings, Inc. (NYSE:RFL  Get Rating) during the third quarter, HoldingsChannel.com reports. The fund bought 19,616 shares of the companys stock, valued at approximately $35,000. A number of other hedge funds have also made ...

Aptus Capital Advisors LLC Makes New Investment in Rafael Holdings, Inc. (NYSE:RFL)

NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. We are pleased to have successfully completed the sale of our real estate asset located in Newark NJ during ...

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and focus on exploring strategic opportunities to invest ...

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. The Real Estate segment refers to the real estate holdings. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals. The company was founded in 2017 and is headquartered in Newark, NJ.

Watchers	1,542
52-Wk Low	$1.55
52-Wk High	$2.52

Market Cap	$47.37M
Volume (M)	4,831.00
52-Wk High	$2.52
52-Wk Low	$1.55

RFL Rafael Holdings Inc - Ordinary Shares - Class B

About

Feed

News

Sentiment

Earnings

Fundamentals